Acne Vulgaris

Arazlo™ (tazarotene; Bausch Health Companies) Lotion 0.045% is now available for the topical treatment of acne vulgaris in patients aged ≥9 years.

A novel study examines the relationship between acne vulgaris and irritable bowel syndrome.

Expanding recommendations for less frequent laboratory monitoring of patients with acne ≥35 years old prescribed isotretinoin without baseline laboratory abnormalities is now supported.

As patients with acne often have psychological comorbidities a multidisciplinary approach may yield optimal treatment.

Researchers assessed the incidence of isotretinoin-triggered axial spondyloarthropathy in acne vulgaris patients based on clinical features and MRI findings and examined clinical and radiologic outcomes after drug withdrawal.

Chemical peels of more than 1 acid are just as effective as monotherapy for reducing acne lesions and increasing skin hydration — and produce fewer adverse events.

Acne patients receiving isotretinoin may not need continued testing when experiencing low-grade liver enzyme abnormalities, as most mild elevations do not worsen.